Carbon Black Nanoparticles Impair Acetylation of Aromatic Amine Carcinogens through Inactivation of ArylamineN-Acetyltransferase Enzymes
Source abstract
Abstract
Carbon black nanoparticles (CB NPs) and their respirable aggregates/agglomerates are classified as possibly carcinogenic to humans. In certain industrial work settings, CB NPs coexist with aromatic amines (AA), which comprise a major class of human carcinogens. It is therefore crucial to characterize the interactions of CB NPs with AA-metabolizing enzymes. Here, we report molecular and cellular evidence that CB NPs interfere with the enzymatic acetylation of carcinogenic AA by rapidly binding to arylamine N-acetyltransferase (NAT), the major AA-metabolizing enzyme. Kinetic and biophysical analyses showed that this interaction leads to protein conformational changes and an irreversible loss of enzyme activity. In addition, our data showed that exposure to CB NPs altered the acetylation of 2-aminofluorene in intact lung Clara cells by impairing the endogenous NAT-dependent pathway. This process may represent an additional mechanism that contributes to the carcinogenicity of inhaled CB NPs. Our results add to recent data suggesting that major xenobiotic detoxification pathways may be altered by certain NPs and that this can result in potentially harmful pharmacological and toxicological effects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Air Quality and Health Impacts · Carcinogens and Genotoxicity Assessment · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Univ Paris Diderot, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative, CNRS EAC4413, 75013, Paris, France
Institut Pasteur, Unité de RMN des Biomolécules, 75015, Paris, France
References (36)
Show source-provided references
1. Xia T. · Annu. Rev. Public Health · 2009 · 30 · 13710.1146/annurev.publhealth.031308.100155 ↗
2. Lin Y. · J. Colloid Interface Sci. · 2002 · 255 · 110.1006/jcis.2002.8638 ↗
3. Roller M. · Inhal. Toxicol. · 2009 · 21 · 14410.1080/08958370902942541 ↗
4. International Agency for Research on Cancer · IARC Monogr. Eval. Carcinog. Risks Hum. · 2010 · 93 · 43
5. 2006
6. Wang Z. · Phys. Chem. Chem. Phys. · 2010 · 12 · 301410.1039/b919789c ↗
7. Clayson D. B. · 2001
8. Kim D. · Annu. Rev. Pharmacol. Toxicol. · 2005 · 45 · 2710.1146/annurev.pharmtox.45.120403.100010 ↗
9. National Toxicology Program.11th Report on Carcinogens;U.S. Department of Health and Human Services:Washington, DC, 2005.
10. de Vocht F. · Cancer Epidemiol. · 2009 · 33 · 9410.1016/j.canep.2009.06.013 ↗
11. Cedervall T. · Proc. Natl. Acad. Sci. U.S.A. · 2007 · 104 · 205010.1073/pnas.0608582104 ↗
12. Zhang B. · Nano Lett · 2009 · 9 · 228010.1021/nl900437n ↗
13. Asuri P. · J. Nanosci. Nanotechnol. · 2007 · 7 · 167510.1166/jnn.2007.453 ↗
14. Chakraborti S. · Langmuir · 2010 · 26 · 350610.1021/la903118c ↗
15. Chandra G. · Int. J. Biol. Macromol. · 2010 · 47 · 36110.1016/j.ijbiomac.2010.05.020 ↗
16. Xu Z. · Environ. Sci. Pollut. Res. Int. · 2010 · 17 · 79810.1007/s11356-009-0153-1 ↗
17. Frohlich E. · Toxicol. Appl. Pharmacol. · 2010 · 242 · 32610.1016/j.taap.2009.11.002 ↗
18. Lamb J. G. · Drug Metab. Dispos. · 2010 · 38 · 224610.1124/dmd.110.035238 ↗
19. Dupret J. M. · Curr. Med. Chem. · 2005 · 12 · 31110.2174/0929867053363289 ↗
20. Hein D. W. · Mutat. Res. · 2002 · 506 · 6510.1016/S0027-5107(02)00153-7 ↗
21. Setyan A. · Phys. Chem. Chem. Phys. · 2009 · 11 · 620510.1039/b902509j ↗
22. L’Azou B. · Part. Fibre Toxicol. · 2008 · 5 · 2210.1186/1743-8977-5-22 ↗
23. Hussain S. · Part Fibre Toxicol. · 2010 · 7 · 1010.1186/1743-8977-7-10 ↗
24. Hussain S. · Toxicology · 2009 · 260 · 14210.1016/j.tox.2009.04.001 ↗
25. Dimova S. · Drug Metab. Dispos. · 2001 · 29 · 1349
26. Kulaksiz H. · Proc. Natl. Acad. Sci. U.S.A. · 2002 · 99 · 679610.1073/pnas.102171199 ↗
27. Castell J. V. · Exp. Toxicol. Pathol. · 2005 · 57 · 18910.1016/j.etp.2005.05.008 ↗
28. Clouter A. · Int. J. Biochem. Cell Biol. · 1997 · 29 · 52110.1016/S1357-2725(96)00158-6 ↗
29. Dairou J. · Toxicol. Appl. Pharmacol. · 2009 · 236 · 36610.1016/j.taap.2009.02.010 ↗
30. Sauvain J. J. · Nanotoxicology · 2008 · 2 · 12110.1080/17435390802245716 ↗
31. Rodrigues-Lima F. · Curr Pharm Des · 2004 · 10 · 251910.2174/1381612043383845 ↗
32. Dairou J. · J. Biol. Chem. · 2004 · 279 · 770810.1074/jbc.M311469200 ↗
33. Sreerama N. · Anal. Biochem. · 2000 · 287 · 24310.1006/abio.2000.4879 ↗
34. Magdaleno S. M. · Am. J. Physiol. · 1997 · 272 · L1142
35. Grant D. M. · Mol. Pharmacol. · 1991 · 39 · 18410.1016/S0026-895X(25)10988-7 ↗
36. Wu H. C. · Urol. Res. · 2000 · 28 · 23510.1007/s002400000130 ↗